Intravitreal ranibizumab in the treatment of subretinal neovascularization in a case of punctate inner choroidopathy

2014 ◽  
Vol 89 (3) ◽  
pp. 130-132
Author(s):  
B. Jiménez ◽  
I. Pinilla ◽  
J.A. Cristóbal ◽  
E. Mínguez ◽  
D. Pérez ◽  
...  
Keyword(s):  
Intravitreal Ranibizumab ◽  
Punctate Inner Choroidopathy ◽  
Subretinal Neovascularization

Intravitreal ranibizumab in the treatment of subretinal neovascularization in a case of punctate inner choroidopathy

2011 ◽  
Vol 89 (s248) ◽  
pp. 0-0
Author(s):  
D PEREZ GARCIA ◽  
I PINILLA ◽  
B JIMENEZ DEL RIO ◽  
J IBANEZ ◽  
C PEIRO EMBID ◽  
...  
Keyword(s):  
Intravitreal Ranibizumab ◽  
Punctate Inner Choroidopathy ◽  
Subretinal Neovascularization

scholarly journals Swept Source-Optical Coherence Tomography Angiography for Management of Secondary Choroidal Neovascularization in Punctate Inner Choroidopathy

2021 ◽  
pp. 232-238
Author(s):  
Martin Stattin ◽  
Julia Forster ◽  
Daniel Ahmed ◽  
Katharina Krepler ◽  
Siamak Ansari-Shahrezaei
Keyword(s):  
Optical Coherence Tomography ◽  
Choroidal Neovascularization ◽  
Optical Coherence Tomography Angiography ◽  
Optical Coherence ◽  
Intravitreal Ranibizumab ◽  
Swept Source ◽  
Punctate Inner Choroidopathy ◽  
White Dot Syndrome ◽  
Oral Corticosteroids ◽  
Sd Oct

The purpose was to demonstrate the diagnostic and therapeutic feasibility of swept source-optical coherence tomography angiography (SS-OCTA) by picturing neovascular changes secondary to a rare white dot syndrome following long-term intravitreal ranibizumab (IVR). A 28-year-old Caucasian myopic female presented with visual loss in her right eye only. The clinical examination and multimodal imaging including spectral domain (SD)-OCT, blue-peak autofluorescence, fluorescein, and indocyanine green angiography (HRA Spectralis, Heidelberg Engineering; Heidelberg, Germany) as well as SS-OCTA (DRI Triton, Topcon; Tokyo, Japan) led to the diagnosis of idiopathic punctate inner choroidopathy with secondary subfoveal choroidal neovascularization (CNV). In addition to oral corticosteroids, a pro re nata regimen with IVR was initiated and guided by repeated SD-OCT and SS-OCTA. Six IVR were administered based on functional SS-OCTA en face scans illustrating vessel transformation and downsizing of the CNV area while SD-OCT B-scans were inconclusive as indirect signs of activity were absent throughout the follow-up period. SS-OCTA provided new possibilities for monitoring vessel development. IVR was managed based on vessel density as displayed by SS-OCTA.

Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A

2009 ◽  
Vol 87 (8) ◽  
pp. 930-932 ◽  
Author(s):  
Nikolaos Mavrakanas ◽  
Efstratios Mendrinos ◽  
Constantin J. Pournaras ◽  
Joel Salzmann
Keyword(s):  
Intravitreal Ranibizumab ◽  
Subretinal Neovascularization

scholarly journals Treatment of Punctate Inner Choroidopathy with Choroidal Neovascularization Using Corticosteroid and Intravitreal Ranibizumab

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Wei Wu ◽  
Shiying Li ◽  
Haiwei Xu ◽  
Yong Liu ◽  
Yi Wang ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Choroidal Neovascularization ◽  
Oral Corticosteroid ◽  
Fundus Autofluorescence ◽  
Intravitreal Ranibizumab ◽  
Punctate Inner Choroidopathy ◽  
Corrected Visual Acuity ◽  
Before And After ◽  
Ranibizumab Treatment

Background. To evaluate the treatment outcomes of patients with punctate inner choroidopathy (PIC) and secondary choroidal neovascularization (CNV). Methods. This is a retrospective study of 24 eyes in 22 patients suffering from PIC with CNV. Patients were treated with intravitreal ranibizumab monotherapy (14 eyes) or combined oral corticosteroid and intravitreal ranibizumab therapy (corticosteroid-ranibizumab group, 10 eyes). Mean follow-up duration was 24.0 months. We evaluated best-corrected visual acuity (BCVA), fundus autofluorescence, fluorescein angiography, indocyanine green angiography, and optical coherence tomography, before and after treatment. The following variables were compared between groups: number of intravitreal ranibizumab injections, BCVA, recurrence of CNV, and change in PIC lesions. Results. The ranibizumab monotherapy group received an average of 3 intravitreal ranibizumab injections; mean logMAR visual acuity improvement was 0.34, and 8 eyes developed recurrent CNV during follow-up. The corticosteroid-ranibizumab group received an average of 1.9 intravitreal ranibizumab injections; mean logMAR visual acuity improvement was 0.61, and there was no recurrence of CNV. Combined corticosteroid-ranibizumab therapy also resulted in better resolution of PIC lesions and fewer new PIC lesions. Conclusion. Both corticosteroid-ranibizumab treatment and ranibizumab monotherapy could significantly improve the vision of PIC patients with CNV. Combined corticosteroid and intravitreal ranibizumab treatment appeared to reduce CNV recurrence and development of new PIC lesions compared with ranibizumab monotherapy.

Intravitreal ranibizumab (Lucentis®) in the treatment of choroidal neovascular membrane secondary to punctate inner choroidopathy

2010 ◽  
Vol 85 (4) ◽  
pp. 149-152
Author(s):  
A. Valverde Megías ◽  
P. Arriola Villalobos ◽  
J. Reche Frutos ◽  
J. Donate López ◽  
C. Calvo González ◽  
...  
Keyword(s):  
Choroidal Neovascular Membrane ◽  
Intravitreal Ranibizumab ◽  
Punctate Inner Choroidopathy
Sign in / Sign up

Export Citation Format

Share Document